专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2305193A1 Sustained analgesia achieved with buprenorphine 失效
标题翻译：用丁丙诺啡持续镇痛
公开(公告)号：EP2305193A1
公开(公告)日：2011-04-06
申请号：EP10185237.4
申请日：1998-02-24
申请人： EURO-CELTIQUE S.A.
发明人： Reder, Robert, F. , Goldenheim, Paul, D. , Kaiko, Robert, F.
IPC分类号： A61F13/00 , A61K31/485 , A61K9/70 , A61P25/04
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/0019 , A61K9/7023 , A61K9/7053 , A61K9/7061 , A61K31/4748
摘要： A transdermal delivery device comprising buprenorphine, for use in treating pain in a patient for a dosing interval of 5 to 9 days by applying onto the skin of the patient the transdermal delivery device comprising an amount of buprenorphine sufficient for about 3 days, and maintaining the transdermal buprenorphine delivery device in contact with the skin of the human patient from 2 to 6 additional days.
摘要翻译：一种包含丁丙诺啡的透皮递送装置，用于通过在患者的皮肤上施用包含足以维持约3天的量的丁丙诺啡的透皮递送装置，以5至9天的给药间隔治疗患者的疼痛，透皮的丁丙诺啡递送装置与人类患者的皮肤接触2至6天。

2. 发明公开

EP2266564A1 Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist 无效
标题翻译：口服含有阿片样物质激动剂的组合和阿片样物质拮抗剂给药的剂型
公开(公告)号：EP2266564A1
公开(公告)日：2010-12-29
申请号：EP10179026.9
申请日：1998-12-22
申请人： Euro-Celtique S.A.
发明人： Kaiko, Robert, F. , Colucci, Robert, D.
IPC分类号： A61K31/485
CPC分类号： A61K31/485 , A61K31/16 , A61K31/60 , A61K45/06 , Y10S514/81 , Y10S514/812 , A61K2300/00
摘要： The invention relates to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject when administered at the same dose or at a higher dose than the usually prescribed dose of opioid agonist.
摘要翻译：本发明涉及一种口服剂型，其包含口服止痛有效量的口服活性阿片样物质拮抗剂的阿片样激动剂和的组合，所述阿片样物质拮抗剂被包括在比所述阿片类激动剂是提供一种组合产品，所有这一切是镇痛有效当组合是口服给药，但所有这些都处于身体依赖性受试者厌恶当以相同剂量或以比一般阿片样物质激动剂的处方剂量高的剂量施用。

3. 发明授权

EP1570823B1 A buprenorphine transdermal patch for use in the treatment of pain for a dosing interval of at least 4 days 失效
标题翻译：透皮贴剂具有为丁丙诺啡在治疗疼痛的用途为至少4天的给药间隔
公开(公告)号：EP1570823B1
公开(公告)日：2011-12-28
申请号：EP05011213.5
申请日：1998-02-24
申请人： EURO-CELTIQUE S.A.
发明人： Reder, Robert, F. , Goldenheim, Paul, D. , Kaiko, Robert, F.
IPC分类号： A61F13/00 , A61K31/485 , A61K9/70 , A61P25/04
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/0019 , A61K9/7023 , A61K9/7053 , A61K9/7061 , A61K31/4748
摘要： A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero order kinetics over at least 2 more days.
摘要翻译：丁丙诺啡的缓释制剂是新的。所述组合物包含透皮递送装置，该装置在三天给药间隔所以没的20 10 1052微克/ ml的最大血浆浓度，获得提供丁丙诺啡的一级释放。该设备则提供了至少两天零代动力学。

4. 发明公开

EP2301494A1 Sustained analgesia achieved with buprenorphine 失效
标题翻译：用丁丙诺啡持续镇痛
公开(公告)号：EP2301494A1
公开(公告)日：2011-03-30
申请号：EP10185241.6
申请日：1998-02-24
申请人： EURO-CELTIQUE S.A.
发明人： Reder, Robert, F. , Goldenheim, Paul, D. , Kaiko, Robert, F.
IPC分类号： A61F13/00 , A61K31/485 , A61K9/70 , A61P25/04
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/0019 , A61K9/7023 , A61K9/7053 , A61K9/7061 , A61K31/4748
摘要： A transdermal delivery device containing buprenorphine for treating human patients suffering from opioid addiction by applying onto the skin of the patient and maintaining the transdermal delivery device in contact with the skin for a 3 day dosing interval, the transdermal delivery device containing an amount of buprenorphine sufficient to maintain an adequate relative release rate to provide a plasma concentration of from about 1000 pg/ml to about 10,000 pg/ml at the end of said 3 day dosing interval, and the transdermal delivery device being maintained in contact with the skin of the patient for at least 2 to about 5 additional days beyond said 3 day dosing interval, such that the patient continues to receive effective treatment for opioid addiction from said transdermal buprenorphine delivery device over said dosing interval.
摘要翻译：一种含有丁丙诺啡的透皮给药装置，用于治疗患有阿片样物质成瘾的人类患者，所述装置通过施用到患者的皮肤上并保持透皮给药装置与皮肤接触3天的给药间隔，该经皮给药装置含有足够量的丁丙诺啡以维持足够的相对释放速率以在所述3天给药间隔结束时提供约1000pg / ml至约10,000pg / ml的血浆浓度，并且透皮递送装置与患者的皮肤保持接触在所述3天给药间隔之后至少2至约5天，使得患者在所述给药间隔内继续接受来自所述透皮性丁丙诺啡递送装置的阿片样物质成瘾的有效治疗。

5. 发明公开

EP1570823A2 Substained analgesia achieved with buprenorphine 失效
标题翻译：透皮贴剂具有为丁丙诺啡在治疗疼痛的用途为至少4天的给药间隔
公开(公告)号：EP1570823A2
公开(公告)日：2005-09-07
申请号：EP05011213.5
申请日：1998-02-24
申请人： Euro-Celtique S.A.
发明人： Reder, Robert, F. , Goldenheim, Paul, D. , Kaiko, Robert, F.
IPC分类号： A61F13/00 , A61K31/485 , A61K9/70 , A61P25/04
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/0019 , A61K9/7023 , A61K9/7053 , A61K9/7061 , A61K31/4748
摘要： The use of buprenorphine in the preparation of a medicament for a method of effectively treating pain in humans is achieved by administering buprenorphine in a manner indicative of first order pharmacokinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in a manner indicative of zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
摘要翻译：在制备用于治疗的有效治疗人类疼痛的方法使用丁丙诺啡的是通过在指示第一顺序的药代动力学在初始3天的给药间隔的方式管理丁丙诺啡实现，检查了来自约20做了最大血浆浓度微克/毫升到约1052微克/毫升达到，并且此后保持丁丙诺啡的给药以指示零级动力学的方式至少在两个额外的天给药间隔，检查没有患者经历镇痛遍及所述至少两天额外给药间隔。

6. 发明授权

EP1731152B1 Sustained analgesia achieved with transdermal delivery of buprenorphine 失效
标题翻译：与丁丙诺啡的透皮给药获得延迟镇痛
公开(公告)号：EP1731152B1
公开(公告)日：2013-05-01
申请号：EP06118876.9
申请日：1998-02-24
申请人： EURO-CELTIQUE S.A.
发明人： Reder, Robert, F. , Goldenheim, Paul, D. , Kaiko, Robert, F.
IPC分类号： A61F13/00 , A61K31/485 , A61K9/70 , A61P25/04
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/0019 , A61K9/7023 , A61K9/7053 , A61K9/7061 , A61K31/4748
摘要： A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero order kinetics over at least 2 more days.

7. 发明授权

EP2266564B1 Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist 无效
标题翻译：口服含有阿片样物质激动剂的组合和阿片样物质拮抗剂给药的剂型
公开(公告)号：EP2266564B1
公开(公告)日：2013-03-13
申请号：EP10179026.9
申请日：1998-12-22
申请人： Euro-Celtique S.A.
发明人： Kaiko, Robert, F. , Colucci, Robert, D.
IPC分类号： A61K31/485 , A61K31/16 , A61K31/60 , A61K45/06
CPC分类号： A61K31/485 , A61K31/16 , A61K31/60 , A61K45/06 , Y10S514/81 , Y10S514/812 , A61K2300/00

8. 发明授权

EP2305194B1 A buprenorphine transdermal patch for use in the treatment of pain for a dosing interval of at least 7 days 无效
标题翻译：透皮贴剂具有为丁丙诺啡在治疗疼痛的用途为7天的给药间隔
公开(公告)号：EP2305194B1
公开(公告)日：2012-05-09
申请号：EP10185240.8
申请日：1998-02-24
申请人： EURO-CELTIQUE S.A.
发明人： Reder, Robert, F. , Goldenheim, Paul, D. , Kaiko, Robert, F.
IPC分类号： A61F13/00 , A61K31/485 , A61K9/70 , A61P25/04
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/0019 , A61K9/7023 , A61K9/7053 , A61K9/7061 , A61K31/4748
摘要： A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero order kinetics over at least 2 more days.
摘要翻译：丁丙诺啡的缓释制剂是新的。所述组合物包含透皮递送装置，该装置在三天给药间隔所以没的20 10 1052微克/ ml的最大血浆浓度，获得提供丁丙诺啡的一级释放。该设备则提供了至少两天零代动力学。

9. 发明公开

EP1570823A3 Substained analgesia achieved with buprenorphine 失效
标题翻译： Analgetisch wirksame Zusammensetzung mitverzögerterWirkstoffabgabe von Buprenorphin
公开(公告)号：EP1570823A3
公开(公告)日：2006-01-18
申请号：EP05011213.5
申请日：1998-02-24
申请人： Euro-Celtique S.A.
发明人： Reder, Robert, F. , Goldenheim, Paul, D. , Kaiko, Robert, F.
IPC分类号： A61F13/00 , A61K31/485 , A61K9/70 , A61P25/04
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/0019 , A61K9/7023 , A61K9/7053 , A61K9/7061 , A61K31/4748
摘要： The use of buprenorphine in the preparation of a medicament for a method of effectively treating pain in humans is achieved by administering buprenorphine in a manner indicative of first order pharmacokinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in a manner indicative of zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
摘要翻译：丁丙诺啡的持续释放配方是新的。组合物包含透皮递送装置，其在3天给药间隔内提供丁丙诺啡的一级释放，使得获得20×10 10 2 pg / ml的最大血浆浓度。该装置然后在至少2天以上提供零级动力学。

10. 发明公开

EP2305194A1 Sustained analgesia achieved with buprenorphine 无效
标题翻译：透皮贴剂具有为丁丙诺啡在治疗疼痛的用途为7天的给药间隔
公开(公告)号：EP2305194A1
公开(公告)日：2011-04-06
申请号：EP10185240.8
申请日：1998-02-24
申请人： EURO-CELTIQUE S.A.
发明人： Reder, Robert, F. , Goldenheim, Paul, D. , Kaiko, Robert, F.
IPC分类号： A61F13/00 , A61K31/485 , A61K9/70 , A61P25/04
CPC分类号： A61K31/485 , A61K9/0014 , A61K9/0019 , A61K9/7023 , A61K9/7053 , A61K9/7061 , A61K31/4748
摘要： The use of buprenorphine in the preparation of a medicament for a method of effectively treating pain in humans is achieved by administering buprenorphine in a manner indicative of first order pharmacokinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in a manner indicative of zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式